HILO MEDICAL CENTER
1. Target Overview & Investment Thesis
HILO MEDICAL CENTER is a 194-bed safety-net/medicaid heavy in HAWAII, HI with $263.6M in net patient revenue and a -19.5% operating margin. The hospital serves a payer mix of 20.0% Medicare, 29.4% Medicaid, and 50.6% commercial.
Thesis: Undervalued. Our ML models identify $19.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -19.5% to -12.1% (+736bps).
| Net Revenue HCRIS | $263.6M |
| Current EBITDA COMPUTED | $-51.3M |
| Operating Margin COMPUTED | -19.5% |
| Occupancy HCRIS | 80.9% |
| Revenue / Bed COMPUTED | $1.4M |
| Net-to-Gross HCRIS | 36.8% |
| Distress Probability ML | 47.8% |
2. Market Context & Competitive Position
HI has 26 Medicare-certified hospitals with a median operating margin of -14.7%. The target's margin of -19.5% places it below the state median. Among 1973 size-comparable peers (97-388 beds), the median margin is -3.8%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (97-388), prioritizing same-state peers. 1973 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| HILO MEDICAL CENTER (Target) | HI | 194 | $263.6M | -19.5% |
| MAYO CLINIC HOSPITAL | AZ | 315 | $2.25B | 1.4% |
| RAINBOW BABIES & CHILDRENS HOS | OH | 231 | $2.22B | -5.0% |
| EASTERN MAINE MEDICAL CENTER | ME | 352 | $2.05B | 48.1% |
| ARTHUR G JAMES CANCER HOSPITAL | OH | 356 | $1.95B | 21.0% |
| MOFFITT CANCER CENTER | FL | 218 | $1.91B | 16.0% |
| BANNER ESTRELLA MEDICAL CENTER | AZ | 317 | $1.84B | 79.2% |
| CITY OF HOPE NATIONAL MEDICAL | CA | 217 | $1.83B | -10.7% |
| SEATTLE CHILDRENS HOSPITAL | WA | 350 | $1.70B | 5.7% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.4M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $5.5M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $5.3M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $5.2M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $3.2M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $169K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-51.3M |
| + RCM Uplift | +$19.4M |
| Pro Forma EBITDA | $-31.9M |
| Current Margin | -19.5% |
| Pro Forma Margin | -12.1% |
| WC Released (1x) | $10.1M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-78.9M | $-144.2M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-78.9M | $-184.3M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-71.0M | $-145.9M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-71.0M | $-180.1M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-86.8M | $-215.6M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-86.8M | $-265.4M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (29.4%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 1973 hospitals with 97-388 beds
- Same-state prioritization (n=8)
- Comp margins: P25=-13.8% / P50=-3.8% / P75=6.2%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.